Analyzing individual patient-level data (IPD) from completed clinical trials to glean additional insights about patient populations is a key benefit of data sharing and reuse. Dr. Ashley Hopkins and his research colleagues have identified clinical trial data as an important source of information, particularly on emerging treatments which may not yet have a large pool of real world data. They have successfully leveraged data from the Vivli platform across multiple health areas, with a particular focus in oncology, including across lung, breast, and neural cancers.

In a recent conversation with Vivli, Dr. Hopkins talked about his research projects, including a recent example involving a significant finding related to potential associations between proton pump inhibitor use and outcomes with the monoclonal antibody atezolizumab. When used in combination with bevacizumab (another monoclonal antibody), and chemotherapy medications such as carboplatin and paclitaxel, the research team identified associations which could alter survival outcomes.

Dr. Hopkins and his colleagues have also used IPD available on the Vivli platform to inform a number of other questions, which have produced multiple publications over the last several years.

“I come from a perspective of being a pharmacist, which has led me on a journey and transition across the research,” said Dr. Hopkins. “I still want to be able to provide patients with the best possible information about the medicines.”

Read more about Dr. Hopkins’ research:

Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials (Journal of Thoracic Oncology)

Interested in finding out more about how access to Vivli’s data repository can help advance your research? Find out more about how to search and request data.